Evaluation of adjunct extended-release quetiapine fumarate on sleep disturbance and quality in patients with major depressive disorder and an inadequate response to on-going antidepressant therapy

International Journal of Neuropsychopharmacology

Volumn 16, Issue 8, 2013, Pages 1755-1765

  Bauer, Michael ^a   McIntyre, Roger S ^b   Szamosi, Johan ^c   Eriksson, Hans ^c  

^a UNIVERSITY HOSPITAL CARL GUSTAV CARUS   (Germany)

^b UNIVERSITY HEALTH NETWORK   (Canada)

^c ASTRAZENECA R AND D   (Sweden)

Author keywords

Adjunct therapy; Atypical antipsychotic; Major depressive disorder; Quetiapine XR; Sleep disturbance and quality

Indexed keywords

AMFEBUTAMONE; AMITRIPTYLINE; CITALOPRAM; DULOXETINE; ESCITALOPRAM; FLUOXETINE; PAROXETINE; PLACEBO; QUETIAPINE; SERTRALINE; VENLAFAXINE;

ADULT; AGED; ARTICLE; CONTROLLED STUDY; DOUBLE BLIND PROCEDURE; DRUG DOSE TITRATION; DRUG EFFICACY; DRUG TOLERABILITY; HAMILTON SCALE; HUMAN; INSOMNIA; MAJOR CLINICAL STUDY; MAJOR DEPRESSION; MONTGOMERY ASBERG DEPRESSION RATING SCALE; PITTSBURGH SLEEP QUALITY INDEX; PRIORITY JOURNAL; SLEEP DISORDER; SLEEP QUALITY; TREATMENT OUTCOME;

ADOLESCENT; ADULT; AGED; ANTIPSYCHOTIC AGENTS; DEPRESSIVE DISORDER, MAJOR; DIBENZOTHIAZEPINES; DOUBLE-BLIND METHOD; FEMALE; HUMANS; MALE; MIDDLE AGED; PSYCHIATRIC STATUS RATING SCALES; SLEEP DISORDERS; TIME FACTORS; TREATMENT OUTCOME; YOUNG ADULT;

EID: 84883034019     PISSN: 14611457     EISSN: 14695111     Source Type: Journal    
DOI: 10.1017/S146114571300031X     Document Type: Article

References (41)

1. APA (2000) Diagnostic and statistical manual of mental disorders, 4th edn., Text Revision. Washington, DC: American Psychiatric Association
2. Asche CV, Joish VN, Camacho F, Drake CL (2010) The direct costs of untreated comorbid insomnia in a managed care population with major depressive disorder. Curr Med Res Opin 26: 1843-1853.
3. AstraZeneca (2012a) Seroquel XR (quetiapine fumarate) extended-release tablets/US prescribing information. http://www1.astrazeneca-us.com/pi/ seroquelxr.pdf
4. AstraZeneca (2012b) Seroquel XR - Summary of Product Characteristics for Ireland. http://www.medicines.ie/medicine/13032/SPC/ Seroquel+XR+50mg%2c+150mg%2c+200mg %2c+300mg%2c+400mg+prolonged-release+tablets/
5. Bauer M, El-Khalili N, Datto C, Szamosi J, Eriksson H (2010) A pooled analysis of two randomised, placebo-controlled studies of extended release quetiapine fumarate adjunctive to antidepressant therapy in patients with major depressive disorder. J Affect Disord 127: 19-30.
6. Bauer M, Pretorius HW, Constant EL, Earley WR, Szamosi J, Brecher M (2009) Extended-release quetiapine as adjunct to an antidepressant in patients with major depressive disorder: results of a randomized, placebo-controlled, double-blind study. J Clin Psychiatry 70: 540-549.
7. Bernert RA, Joiner TE (2007) Sleep disturbances and suicide risk: a review of the literature. Neuropsychiatr Dis Treat 3: 735-743.
8. Bortnick B, El-Khalili N, Banov M, Adson D, Datto C, Raines S, Earley W, Eriksson H (2011) Efficacy and tolerability of extended release quetiapine fumarate (quetiapine XR) monotherapy in major depressive disorder: a placebocontrolled, randomized study. J Affect Disord 128: 83-94.
9. Brecht S, Kajdasz D, Ball S, Thase ME (2008) Clinical impact of duloxetine treatment on sleep in patients with major depressive disorder. Int Clin Psychopharmacol 23: 317-324.
10. Buysse DJ, Reynolds CF III, Monk TH, Berman SR, Kupfer DJ (1989) The Pittsburgh Sleep Quality Index: a new instrument for psychiatric practice and research. Psychiatry Res 28: 193-213.
11. Carney CE, Segal ZV, Edinger JD, Krystal AD (2007) A comparison of rates of residual insomnia symptoms following pharmacotherapy or cognitive-behavioral therapy for major depressive disorder. J Clin Psychiatry 68: 254-260.
12. Cho HJ, Lavretsky H, Olmstead R, Levin MJ, Oxman MN, Irwin MR (2008) Sleep disturbance and depression recurrence in community-dwelling older adults: a prospective study. Am J Psychiatry 165: 1543-1550.
13. Cutler AJ, Montgomery SA, Feifel D, Lazarus A, Åström M, Brecher M (2009) Extended release quetiapine fumarate monotherapy in major depressive disorder: a placebo- and duloxetine-controlled study. J Clin Psychiatry 70: 526-539.
14. Datto C, Berggren L, Patel JB, Eriksson H (2009) Self-reported sedation profile of immediate-release quetiapine fumarate compared with extended-release quetiapine fumarate during dose initiation: a randomized, double-blind, crossover study in healthy adult subjects. Clin Ther 31: 492-502.
15. Duru G, Fantino B (2008) The clinical relevance of changes in the Montgomery-Åsberg Depression Rating Scale using the minimum clinically important difference approach. Curr Med Res Opin 24: 1329-1335.
16. El-Khalili N, Joyce M, Atkinson S, Buynak RJ, Datto C, Lindgren P, Eriksson H (2010) Extended-release quetiapine fumarate (quetiapine XR) as adjunctive therapy in major depressive disorder (MDD) in patients with an inadequate response to ongoing antidepressant treatment: a multicentre, randomized, double-blind, placebo-controlled study. Int J Neuropsychopharmacol 13: 917-932.
17. Fava GA, Ruini C, Belaise C (2007) The concept of recovery in major depression. Psychol Med 37: 307-317.
18. Fava M, Graves LM, Benazzi F, Scalia MJ, Iosifescu DV, Alpert JE, Papakostas GI (2006) A cross-sectional study of the prevalence of cognitive and physical symptoms during long-term antidepressant treatment. J Clin Psychiatry 67: 1754-1759.
19. FavaM, Hoog SL, Judge RA, Kopp JB, NilssonME, Gonzales JS (2002) Acute efficacy of fluoxetine vs. sertraline and paroxetine in major depressive disorder including effects of baseline insomnia. J Clin Psychopharmacol 22: 137-147.
20. Hamilton M (1960) A rating scale for depression. J Neurol Neurosurg Psychiatry 23: 56-62.
21. Iglesias C, Alonso M (2009) Residual symptoms in depression. Actas Esp Psiquiatr 37: 101-105.
22. Kessler RC, Berglund P, Demler O, Jin R, Koretz D, Merikangas KR, Rush AJ, Walters EE, Wang PS (2003) The epidemiology of major depressive disorder: results from the National Comorbidity Survey Replication (NCS-R). J Am Med Assoc 289: 3095-3105.
23. Knutson KL, Van Cauter E (2008) Associations between sleep loss and increased risk of obesity and diabetes. Ann N Y Acad Sci 1129: 287-304.
24. Lader M, Andersen HF, Baekdal T (2005) The effect of escitalopram on sleep problems in depressed patients. Hum Psychopharmacol 20: 349-354.
25. Lemoine P, Guilleminault C, Alvarez E (2007) Improvement in subjective sleep in major depressive disorder with a novel antidepressant, agomelatine: randomized, doubleblind comparison with venlafaxine. J Clin Psychiatry 68: 1723-1732.
26. Liebowitz M, Lam RW, Lepola U, Datto C, Sweitzer D, Eriksson H (2010) Efficacy and tolerability of extended release quetiapine fumarate monotherapy as maintenance treatment of major depressive disorder: a randomized, placebo-controlled trial. Depress Anxiety 27: 964-976.
27. Lopez AD, Murray CC (1998) The global burden of disease, 1990-2020. Nat Med 4: 1241-1243.
28. McCall WV, Blocker JN, D'Agostino R Jr., Kimball J, Boggs N, Lasater B, Rosenquist PB (2010) Insomnia severity is an indicator of suicidal ideation during a depression clinical trial. Sleep Med 11: 822-827.
29. Mayers AG, Baldwin DS (2005) Antidepressants and their effect on sleep. Hum Psychopharmacol 20: 533-559.
30. Mendlewicz J (2009) Sleep disturbances: core symptoms of major depressive disorder rather than associated or comorbid disorders. World J Biol Psychiatry 10: 269-275.
31. Montgomery SA, Åsberg M (1979) A new depression scale designed to be sensitive to change. Br J Psychiatry 134: 382-389.
32. Nelson JC, Mankoski R, Baker RA, Carlson BX, Eudicone JM, Pikalov A, Tran QV, Berman RM (2010) Effects of aripiprazole adjunctive to standard antidepressant treatment on the core symptoms of depression: a post-hoc, pooled analysis of two large, placebo-controlled studies. J Affect Disord 120: 133-140.
33. Nierenberg AA, Husain MM, Trivedi MH, Fava M, Warden D, Wisniewski SR, Miyahara S, Rush AJ (2010) Residual symptoms after remission of major depressive disorder with citalopram and risk of relapse: a STAR*D report. Psychol Med 40: 41-50.
34. Ruger M, Scheer FA (2009) Effects of circadian disruption on the cardiometabolic system. Rev Endocr Metab Disord 10: 245-260.
35. Shelton RC, Hollon SD, Wisniewski SR, Alpert JE, Balasubramani GK, Friedman ES, Rush AJ, Trivedi MH, Preskorn SH (2009) Factors associated with concomitant psychotropic drug use in the treatment of major depression: a STAR*D Report. CNS Spectr 14: 487-498.
36. Spiegel K, Leproult R, Van Cauter E (2003) Impact of sleep debt on physiological rhythms. Rev Neurol (Paris) 159: 6S11-6S20.
37. Thase ME (2006) Depression and sleep: pathophysiology and treatment. Dialogues Clin Neurosci 8: 217-226.
38. van Mill JG, Hoogendijk WJ, Vogelzangs N, van Dyck R, Penninx BW (2010) Insomnia and sleep duration in a large cohort of patients with major depressive disorder and anxiety disorders. J Clin Psychiatry 71: 239-246.
39. Weisler R, Joyce M, McGill L, Lazarus A, Szamosi J, Eriksson H (2009) Extended release quetiapine fumarate monotherapy for major depressive disorder: results of a double-blind, randomized, placebo-controlled study. CNS Spectr 14: 299-313.
40. Wojnar M, Ilgen MA,Wojnar J, McCammon RJ, Valenstein M, Brower KJ (2009) Sleep problems and suicidality in the National Comorbidity Survey Replication. J Psychiatr Res 43: 526-531.
41. WHO (2008) The global burden of disease 2004 update. http://www.who.int/ healthinfo/global-burden-disease/GBD- report-2004update-full.pdf